First day of the IPO | Hansi AT-B (03378) was first listed and opened 9.69% lower in early trading. The core product, HX009, is undergoing three clinical projects in China

The Zhitong Finance App learned that Hansai Tai-B (03378) was first listed. According to the announcement, the price was HK$32 per share. A total of 18.321 million shares were issued, 100 shares per lot, with a net proceeds of about HK$531 million. As of press release, it decreased by 9.69% to HK$28.9, with a turnover of HK$756.97 million.

According to the prospectus, Hansai is a biotechnology company with independent expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, Hansi Aitai has developed a product pipeline, including one core product and nine candidate products for other pipelines, namely three clinical-stage drug candidates for oncology, including core products HX009 and main products HX301 and HX044; and seven pre-clinical drug candidates, including antibody-conjugated drugs, bispecific antibodies, and monoclonal antibodies for the autoimmune and oncology markets.

According to public information, Hx009, the core product of Hansatec, is a bispecific antibody fusion protein that simultaneously targets CD47 and PD-1. According to the Frost & Sullivan report, as of the last practical date, clinical trial progress of HX009 is leading the world in similar CD47 targeting bispecific antibody/bifunctional fusion protein products.